Results: Total serum bilirubin after clofibrate administration was lower than control the group (F= 6.48, P=0.02); however, the duration of phototherapy and hospitalization were not significantly different between the two groups (P=0.39 and 0.91 respectively). Based on the physical exam and liver function tests, no side effects of drug were observed.
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Conclusion:
These findings suggest that clofibrate maintained total serum bilirubin lower in very low birth weight neonates but without effect on duration of phototherapy and hospitalization. 
INTRODUCTION

38
Hyperbilirubinemia occurs in 80% of preterm infants. In these babies hyperbilirubinemia is 39 higher, more persistent, longer and more likely to be associated with neurological injury than 40 term neonates. The increased intensity and duration of hyperbilirubinemia in preterm infants 41 as well as the immaturity of the blood -brain barrier have led to concern about greater risk 42 of bilirubin encephalopathy in preterm infants [1, 2, 3] . Deficient uridin glucuronyl transferase 43 (UDPG-T) activity that results bilirubin conjugation impairment has long been considered a 44 major cause leading physiologic jaundice. In the first 10 days of life the UDPG-T activity in 45 full term and premature neonates is usually less than 1% of adult values [3, 4] . 46
There are three methods for the treatment of hyperbilirubinemia such as: Exchange 47 transfusion for mechanical removal of bilirubin, phototherapy for bilirubin excretion in stool or 48 urine and pharmacologic way which accelerates normal metabolic pathway for bilirubin 49 excretion. Exchange transfusion is an invasive procedure with many complications and one 50 percent mortality. The most common approach for treatment and prevention of neonatal 51 hyperbilirubinemia is phototherapy, which reduces the incidence of exchange transfusion. 52
This method has some disadvantages including anxiety of parents for baby hospitalization, 53 high expenses and disrupted mother-infant bonding. 54
In neonates and especially very low birth weight infant UDPG-T activity is very low; 55 therefore any inducer of UDPG-T activity will prevent hyperbilirubinemia. Several 56 pharmacologic agents are capable to stimulate the hepatic glucuronyl conjugating system 57 and some have even been used to reduce the concentration of serum bilirubin in newborn 58
infants. 59
Phenobarbital is the most widely used drug in human studies. It is a potent inducer of 60 microsomal enzymes that increase bilirubin conjugation. Clofibrate is also a glucuronyl 61 transferase inducer and can increase bilirubin conjugation and excretion [5] [6] . We haveperformed two studies about therapeutic effects of clofibrate on jaundiced term and preterm 63 newborn [7, 8] . Results of these two studies have showed that clofibrate has significant 64 therapeutic effects on term newborns but it does not show a full therapeutic effect on 65 preterm ones. The other research has also been conducted to study the prophylactic effects 66 of clofibrate on very low birth weight neonates. According to this study, clofibrate has 67 prophylactic effects only 24 hours after administration of clofibrate, and also the duration of 68 phototherapy was reduced [9] . In present study, our aim was to assess prophylactic effect of 69 clofibrate on hyperbilirubinemia in very low birth weight twins with the same blood group and 70
sex. 71
Medical treatment is practical, economical and acceptable to parents, so studies about 72
prophylactic and therapeutic effects of drugs on jaundice would be advantageous. 73
MATERIAL AND METHODS
75
In a randomized double blind clinical trial 40 very low birth weight neonates who were 76 admitted to NICU of Imam Reza Hospital of Mashhad university of medical sciences, Iran 77 were studied. Babies with congenital anomalies, metabolic diseases, hemolytic disease and 78 infections were excluded. These neonates were healthy, breastfed twins with birth weight 79 equal or less than 1500 grams with the same blood group and sex. Each pairs of twins were 80 boy or girl and blood groups of them were the same. Laboratory investigations included 81 complete blood count, red blood cell morphology, newborn's blood group and their mother's 82 blood group, direct and indirect coomb's tests, reticulocyte count and erythrocyte G6PD 83 level. The clinical examination, gestational age, birth weight, sex, serial total serum bilirubin 84 (TSB), direct bilirubin, duration of phototherapy and hospitalization were recorded. TSB was 85 measured by using a Unistat bilirubineometer (Reichert -Jung, Germany). 86
For measurement of direct bilirubin the colorimetric method of Lathe and Ruthven were 87 used [10] . As all neonates were healthy preterm babies, phototherapy was started when total 88 serum bilirubin concentration reached a threshold level based on AAP recommendation 89 (TSB 5 grams/dl in babies with less than 750 grams birth weight, TSB 6 grams/dl in 7511000, TSB 7 grams/dl in 1001-1250 and TSB 8 grams/dl in more than 1250 grams birth 91 weight) [3] . 92
Phototherapy was discontinued when bilirubin decreased to 50% of Phototherapy level. 93
Each phototherapy unit contained six blue lamps. Energy output or irradiance of the 94 phototherapy light was being maintained at 8-12 µw/Cm2/nm. Level irradiance of 95 phototherapy was checked routinely by fluoro-LITE meter 451, Minolta camera co. LTD, and 96 maintain at 8 -12 µW/Cm2/nm. 97
The protocol of the study was approved by the local ethical committee of Mashhad 98
University of medical science. The study was described to the parents of neonates before 99 start of the research, and written informed consents were obtained. Babies were randomly 100 divided in two groups. One groups received clofibrate 100mg/kg (clofibrate group n=20) and 101 the other group received sterile water (control group n=20). Both clofibrate and sterile water 102 
RESULTS
115
As the two groups were of the same blood groups and sex twins therefore, gestational age, 116 demographic factors of mothers and newborns in both were the same. Mean gestational age 117 was 31.95± 1.60 weeks and birth weight was 1396± 154 grams in clofibrate group and 118 1408± 106 grams in control group. Some pair of twins was boy and some girl. All type of 119 blood groups were found in participants but each pair of twins had the same blood group. As 120 The effect of phenobarbital on TSB levels begins within a few days of administration; 160 in addition phenobarbital causes respiratory failure, drowsiness and also worsens 161 bilirubin toxicity by alteration of bilirubin oxidation in brain. Clofibrate such as 162 phenobarbital is a hepatic bilirubin metabolism inducer; in addition it can cause 163 100% increase in hepatic bilirubin clearance within six hours, with no drowsiness 164 effect [6] . 165 Gabilan found that clofibrate is a better glucuronyl transferase inducer than other 166 drugs [11] . In this study it was recommended that clofibrate is the only 167 pharmacological treatment of neonatal jaundice available at that time. 168 Bourget et al [6] suggested that a single oral dose of 50 mg/kg clofibrate may be a 169 better treatment for jaundice compared to a single oral dose of 100 mg/kg. 170 Lindenbaum et al. [12] (1981) showed that after 16 hours of treatment mean plasma 171 bilirubin levels are significantly lower in treated group compared to control group. 172
Clofibrate also resulted in a shorter duration of jaundice and a restricted use of 173 phototherapy. 174
In this study, we also found that the mean plasma total bilirubin levels 12, 24 and 48 175 hours after clofibrate administration were significantly lower in term jaundiced 176 neonates compared to the control group (P < 0.0001, P < 0.0001 and P = 0.004, 177 respectively). Nevertheless, treatment with clofibrate resulted in a shorter duration of 178 phototherapy (P < 0.0001) [7] . According to this study, clofibrate maintained total serum bilirubin level lower after 229 its administration, but had no effect on duration of phototherapy and 230 hospitalization. Further investigation should be conducted about drug metabolism 231 and effects of frequent doses on preterm neonates in order to discover all its 232 therapeutic and prophylactic properties and side effects.
